The Abramson Cancer Center facilitates interdisciplinary cancer research, education, and patient care. Its 299 members are drawn from 41 Departments and eight Schools of the University and have $120,755,622 million in research and training (annual direct costs), a 73% increase in the past five years, of which $111,281,669 is peer-reviewed and $56,709,782 is NCI funded (138% increase in the past five years). This includes 20 NIH P01s and seven P50s. John Glick, MD, has served as Director since 1985. Eleven Research Programs comprise the Cancer Center's three Divisions (Fundamental Research, Clinical Research, Cancer Control and Population Sciences). The Cancer Center supports 15 Shared Resources, five of which are new. The development of strong Research Programs and leading-edge Shared Resources, the recruitment of outstanding faculty in areas of priority, and the acquisition of additional research space have enabled the Cancer Center to realize its mission. An ongoing strategic planning process identifies future directions, while guiding current activities and resource allocations. A wide range of seminars and retreats as well as interdisciplinary laboratory space are among the ways in which the Cancer Center sucessfully facilitates interaction and collaboration. Developmental Funds are critical to faculty recruitment and the funding of innovative pilot projects with the potential for peer-reviewed funding, translational research initiatives, and Shared Resources. The Division of Cancer Control and Population Sciences has benefited from the recruitment of Caryn Lerman, PhD, as Associate Director and other significant faculty recruitments. The Clinical Research Division's progress is distinguished by innovative translational research in all Research Programs and a nationally recognized experimental therapeutics effort. In the basic sciences, leadership changes have led to greater activity in translational research and increased collaborations. The Cancer Center continues to meet Comprehensiveness guidelines, and was last approved in 1999.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ogunbiyi, Peter
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Shroff, Rachna T; Hendifar, Andrew; McWilliams, Robert R et al. (2018) Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol 2018:
Fraietta, Joseph A; Lacey, Simon F; Orlando, Elena J et al. (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24:563-571
Anton, Lauren; Sierra, Luz-Jeannette; DeVine, Ann et al. (2018) Common Cervicovaginal Microbial Supernatants Alter Cervical Epithelial Function: Mechanisms by Which Lactobacillus crispatus Contributes to Cervical Health. Front Microbiol 9:2181
Williams, Austin D; Reyes, Sylvia A; Arlow, Renee L et al. (2018) Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged Ann Surg Oncol 25:2875-2883
Krump, Nathan A; Liu, Wei; You, Jianxin (2018) Mechanisms of persistence by small DNA tumor viruses. Curr Opin Virol 32:71-79
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5
Nair, Praful R; Alvey, Cory; Jin, Xiaoling et al. (2018) Filomicelles Deliver a Chemo-Differentiation Combination of Paclitaxel and Retinoic Acid That Durably Represses Carcinomas in Liver to Prolong Survival. Bioconjug Chem 29:914-927
Bhagwat, Neha; Dulmage, Keely; Pletcher Jr, Charles H et al. (2018) An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters. Sci Rep 8:5035
Raposo-Ferreira, Talita M M; Brisson, Becky K; Durham, Amy C et al. (2018) Characteristics of the Epithelial-Mesenchymal Transition in Primary and Paired Metastatic Canine Mammary Carcinomas. Vet Pathol 55:622-633
Kasner, Margaret T; Mick, Rosemarie; Jeschke, Grace R et al. (2018) Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. Invest New Drugs 36:657-666

Showing the most recent 10 out of 1047 publications